The new Midlands & Wales research consortium has received funding to a total of £9 million (£9M from Innovate UK and £2M from other sources) to develop the Midlands & Wales Advanced Therapy Treatment Centre (MW-ATTC). Advanced Therapy Medicinal Products (ATMPs), which can be cell or gene therapies, show great potential in treating patients with conditions that cannot be cured with current treatments. These include liver disease and several types of cancer. The MW-ATTC is one of only three centres in Britain awarded funding from the Industrial Strategy Challenge Fund. The project will last for three years. The aim is to enable UK ATMP companies to reach the clinical market, whilst building clinical capacity across the UK to benefit patient outcomes.
BSG member Professor Philip Newsome is Director of both the MW-ATTC and the University of Birmingham’s Centre for Liver Research. The BSG congratulates him and his team on the funding and looks forward to the potential access to breakthrough medicines that it offers patients with challenging illnesses.
Read the University of Birmingham’s press release for more information.